Technology in Cancer Research & Treatment最新文献

{"title":"Anlotinib as Maintenance Therapy After First-Line Chemotherapy Combined with Consolidation Radiation for Extensive-Stage Small Cell Lung Cancer.","authors":"Jinbo Ma, Xiaoyan Ma, Wei Zhang, Shanliang Hu, Rukun Zang, Xiaolong Wu, Jie Song","doi":"10.1177/15330338251317571","DOIUrl":"10.1177/15330338251317571","url":null,"abstract":"<p><strong>Background: </strong>Small cell lung cancer is sensitive to chemotherapy and radiotherapy, but local recurrence and distant metastasis occur shortly after treatment. This study aimed to evaluate the real-world value of anlotinib as a maintenance therapy in patients with extensive-stage small cell lung cancer (ES-SCLC) after first-line chemotherapy and consolidative thoracic radiotherapy (CTRT).</p><p><strong>Patients and methods: </strong>A total of 150 patients with ES-SCLC treated with first-line chemotherapy and CTRT from April 2017 to December 2021 were retrospectively analyzed. After the completion of chemoradiotherapy, patients received anlotinib according to their desire. The primary endpoints were progression-free survival (PFS) and overall survival (OS) after the first diagnosis, and the secondary endpoints were prognostic factors and safety.</p><p><strong>Results: </strong>The ORR and DCR of patients with ES-SCLC were 50.0% and 80.3%, respectively, in the anlotinib group and 42.9% and 69.0% in the no-maintenance therapy group. The 3-year OS rates were 27.6% and 12.6% in the anlotinib and observation groups (HR = 2.52, <i>P</i> = 0.003), and the median OS times were 23.8 months and 15.3 months. The 3-year PFS rates were 18.2% and 8.8% in the anlotinib and observation groups (HR = 1.76, <i>P</i> = 0.034) with median PFS times of 11.5 months and 8.8 months. After stratification on the basis of clinical response, patients who achieved CR plus PR after chemoradiotherapy had a longer median OS in the anlotinib and observation groups (34.0 months <i>vs</i> 24.8 months, HR = 2.40, <i>P</i> = 0.009). There were higher incidence rates of hand-foot syndrome (27.3% <i>vs</i> 10.5%, <i>P</i> = 0.001), gingival bleeding/hemoptysis (18.5% <i>vs</i> 4.8%, <i>P</i> = 0.015) and rash (33.3% <i>vs</i> 4.8%, <i>P</i> < 0.001) in the anlotinib group than in the observation group.</p><p><strong>Conclusion: </strong>Maintenance therapy with anlotinib improved the survival of patients with ES-SCLC after first-line chemotherapy and CTRT. Owing to the small sample size of the real-world trial, the reliability of our study needs to be confirmed in more studies.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251317571"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11786289/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143068111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Electrochemotherapy for Recurrence and/or Metastatic Skin Cancers: A Prospective Case Series in Iran.","authors":"Seyed Mojtaba YazdanParast, Sepideh Mansouri, Farshid Rostami Pouria, Navid Manoochehri, Kosar Namakin, Alvand Naserghandi, Seyed Rouhollah Miri, Habibollah Mahmoodzadeh, Omid Nabavian, Shirin Zaresharifi, Mohammad Abdolahad","doi":"10.1177/15330338251338635","DOIUrl":"https://doi.org/10.1177/15330338251338635","url":null,"abstract":"<p><p>PurposeThis study aimed to investigate the efficacy of electrochemotherapy on the three common types of skin cancer, including basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (cSCC), and melanoma.Methods26 patients with skin cancer were recruited from single cancer treatment centers from 2022 to 2024. Electrochemotherapy (ECT) was performed to treat the cancerous nodules; all nodules in a patient with multiple lesions were treated. However the biggest lesions were always pointed out (according to European Standard Operating Procedures on Electrochemotherapy protocol) and their clinical response and adverse effects were evaluated during the study.Resultstotally, 104 nodules of 26 patients were assessed. Clinical complete response was achieved in 53 lesions, while partial response was observed in 51 lesions after first month of treatment. The most common adverse effect was pain which was in 65% of cases.ConclusionBCC shows a notably higher clinical complete response rate. Because the research was conducted at a single center and given the novelty of this treatment in Iran, the number of patients included in the study was limited. Electrochemotherapy (ECT) has shown significant clinical effectiveness for superficial tumors, especially for patients who have health issues related to standard therapies or who are resistant to conventional treatments. It is generally well-tolerated, with side effects predominantly consisting of temporary pain. Ongoing research aims to expand its use in deep-seated tumors that are resistant to conventional therapies.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251338635"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12066867/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144052575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incorporating Percutaneous Laser Ablation for Early Breast Cancer Treatment: A Systematic Review.","authors":"Danielle Ramos Martin Matsumoto, Gil Facina","doi":"10.1177/15330338241300743","DOIUrl":"10.1177/15330338241300743","url":null,"abstract":"<p><p><b>Objectives:</b> We conducted a systematic review to compile the findings of all published studies on the use of percutaneous laser ablation (PLA) in the treatment of early-stage breast cancer. We aimed to identify appropriate methodology as well as parameters for the selection of suitable patients to optimize outcomes with the use of PLA. Additionally, we aimed to analyze whether this method is a viable alternative to current surgical treatments employed. <b>Methods:</b> The PRISMA 2020 method was applied. The terms \"laser ablation\" AND \"breast cancer\" were used to select all articles published up to January 2024 on the PubMed and Embase platforms. Articles in English were included. Only original articles were considered for this systematic review. Review articles, editorials, letters, and studies ex-vivo or not performed in humans were excluded. <b>Results:</b> Seventeen articles, including 308 patients were analyzed. Among the studies describing the complete response rate to assess treatment success, there was no residual tumor after ablation in 74.4% of the patients. MRI was the best exam to evaluate the effectiveness of the ablative procedure with a NPV of 92% to 100%. Skin burn was the most commonly observed complication, occurring in 6% of patients. Other less frequent complications were hematoma/bleeding, pain, nodulation, erythema, seroma, and fat necrosis. <b>Conclusions:</b> The use of PLA remains restricted to cases with specific indications or within the context of research protocols. However, future studies may validate this promising technique for the local treatment of early-stage breast cancer. This study was registered at INPLASY (registration number: INPLASY2024100045).</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338241300743"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11898239/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142971968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterization of T-Cell Receptor Profiles Predicts Survival Situation in Patients with Hepatocellular Carcinoma.","authors":"Fengyan Wang, Li Deng, Ziqiang Li, Qiwei Cao, Runze Jiang, Changqing Xu, Jing Yang","doi":"10.1177/15330338251329699","DOIUrl":"10.1177/15330338251329699","url":null,"abstract":"<p><p>PurposeHepatocellular carcinoma (HCC) is the most common liver malignancy in the world, and tumor-infiltrating T cells have been shown to be closely related to the prognosis of HCC. This study investigated the potential and efficacy of T cell receptor (TCR) repertoire characterization as a biomarker for predicting survival differences.MethodsIn this study, we used high-throughput sequencing technology to systematically analyze the characteristics of TCR repertoires in tumor tissues obtained from 23 long-survivors and 8 short-survivors diagnosed with HCC.ResultsThe TCR composition in HCC long-survivors was found to be less diverse than in the short-survivors. In addition, in the context of V and J gene segments, long-survivors showed significantly higher usage of TRBJ1-3, TRBV10-1, TRBV15, and TRBV6-5, and lower usage of TRBJ2-2. Both principal component analysis (PCA) and the motif diagram of complementary determination region 3 (CDR3) sequences could clearly discriminate short- and long-survivors. And there were five up-regulated and one down-regulated CDR3 sequences in the LS group compared with the SS group. According to the characteristics of TCR repertoire, we also established the survival-related evaluation system and the prediction model for the survival period of HCC patients.ConclusionOur study adds to the existing knowledge of TCR rearrangement profiles in HCC patients by elucidating the differential TCR rearrangement profiles between long-term and short-term surviving HCC patients. Also, our analysis identified a number of TCR genes that are significantly associated with survival, and these may not only serve as prognostic biomarkers but may also play an important role in antigen-specific immunotherapy.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251329699"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11954561/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143731678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deep Learning-Based Auto-Segmentation for Liver Yttrium-90 Selective Internal Radiation Therapy.","authors":"Jun Li, Wookjin Choi, Rani Anne","doi":"10.1177/15330338251327081","DOIUrl":"10.1177/15330338251327081","url":null,"abstract":"<p><p>The aim was to evaluate a deep learning-based auto-segmentation method for liver delineation in Y-90 selective internal radiation therapy (SIRT). A deep learning (DL)-based liver segmentation model using the U-Net3D architecture was built. Auto-segmentation of the liver was tested in CT images of SIRT patients. DL auto-segmented liver contours were evaluated against physician manually-delineated contours. Dice similarity coefficient (DSC) and mean distance to agreement (MDA) were calculated. The DL-model-generated contours were compared with the contours generated using an Atlas-based method. Ratio of volume (RV, the ratio of DL-model auto-segmented liver volume to manually-delineated liver volume), and ratio of activity (RA, the ratio of Y-90 activity calculated using a DL-model auto-segmented liver volume to Y-90 activity calculated using a manually-delineated liver volume), were assessed. Compared with the contours generated with the Atlas method, the contours generated with the DL model had better agreement with the manually-delineated contours, which had larger DSCs (average: 0.94 ± 0.01 vs 0.83 ± 0.10) and smaller MDAs (average: 1.8 ± 0.4 mm vs 7.1 ± 5.1 mm). The average RV and average RA calculated using the DL-model-generated volumes are 0.99 ± 0.03 and 1.00 ± 0.00, respectively. The DL segmentation model was able to identify and segment livers in the CT images and provide reliable results. It outperformed the Atlas method. The model can be applied for SIRT procedures.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251327081"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11951913/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143731684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic Value of ¹⁸F-FDG PET/CT Radiomics in Lymphoma: A Systematic Review and Meta-Analysis.","authors":"Chaoying Liu, Jun Zhao, Heng Zhang, Xinye Ni","doi":"10.1177/15330338251342860","DOIUrl":"10.1177/15330338251342860","url":null,"abstract":"&lt;p&gt;&lt;p&gt;IntroductionVarious machine learning models and features have been proposed for lymphoma diagnosis using &lt;sup&gt;18&lt;/sup&gt;F-fluorodeoxyglucose (&lt;sup&gt;18&lt;/sup&gt;F-FDG) PET/CT radiomics. This research aimed to systematically evaluate the diagnostic value of &lt;sup&gt;18&lt;/sup&gt;F-FDG PET/CT radiomics in lymphoma by conducting a meta-analysis.MethodsData from published studies regarding the diagnosis of lymphoma using &lt;sup&gt;18&lt;/sup&gt;F-FDG PET/CT radiomics, from January 2010 to July 2024, were gathered from PubMed, Web of Science, and the Cochrane Library. Following their separate searches and screenings of the literature, two researchers extracted data and assessed the caliber of all the included studies. The quality assessment involved the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2), the Radiomics Quality Score (RQS), and the METhodological RadiomICs Score (METRICS). The meta-analysis was conducted by using RevMan 5.4.1, R 4.4.0, and Stata 17.0 software. Six meta-regressions were conducted on study performance, considering sample size, image modality, region of interest (ROI) selection, ROI segmentation, radiomics mode, and algorithms.ResultsIn total, 20 studies classified as type 2a or above according to the Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD) statement were included for this systematic review and meta-analysis. The studies achieved an average RQS of 13 (ranging from 10 to 17), accounting for 36.1% of the total points. The average METRICS score was 69.3% (ranging from 54.8% to 80.9%). The quality category of the studies is mainly \"good\". The results of our meta-analysis showed that the pooled sensitivity (SEN), specificity (SPE), positive likelihood ratio, negative likelihood ratio and diagnostic odds ratio with 95% confidence interval (&lt;i&gt;CI&lt;/i&gt;) were 0.82 (0.78, 0.88), 0.83 (0.76, 0.87), 4.7 (3.4, 6.6), 0.20 (0.15, 0.28) and 23 (13, 42), respectively. The area under the curve of the summary receiver operating characteristic curve was 0.90 (0.87, 0.92). The results of Spearman correlation analysis revealed no threshold effect among the studies (&lt;i&gt;P&lt;/i&gt; = .423). Significant heterogeneity was observed among the studies (overall &lt;i&gt;I&lt;sup&gt;2&lt;/sup&gt;&lt;/i&gt; = 83.7%; 95% &lt;i&gt;CI&lt;/i&gt;: 76.0, 88.9; &lt;i&gt;P&lt;/i&gt; &lt; .01). Meta-regressions indicated that sample size and ROI selection contributed to the heterogeneity in SEN, while algorithms affected the heterogeneity in SPE (&lt;i&gt;P&lt;/i&gt; &lt; .05). Deeks' test confirmed there was no significant publication bias in all the included studies. The Fagan nomogram showed an absolute increase of 34% in the post-test probability following a positive test result.ConclusionThe results supported that &lt;sup&gt;18&lt;/sup&gt;F-FDG PET/CT radiomics has high diagnostic value for lymphoma. However, there is high heterogeneity among different studies. In the future, clinical practicality needs to be substantiated by more prospective studies with rigorous adherence to existing g","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251342860"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12099142/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144111985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Early Thyroid Screening Model Based on Transformer and Secondary Transfer Learning for Chest and Thyroid CT Images.","authors":"Na Han, Rui Miao, Dongwei Chen, Jinrui Fan, Lin Chen, Siyao Yue, Tao Tan, Bowen Yang, Yapeng Wang","doi":"10.1177/15330338251323168","DOIUrl":"10.1177/15330338251323168","url":null,"abstract":"<p><p>IntroductionThyroid cancer is a common malignant tumor, and early diagnosis and timely treatment are crucial to improve patient prognosis. With the increasing use of enhanced CT scans, a new opportunity for early thyroid cancer screening has emerged. However, existing CT-based models face challenges due to limited datasets, small sample sizes, and high noise.MethodsTo address these challenges, we collected enhanced CT scan image data from 240 patients in Guangdong and Xinjiang, China, and established a CT dataset for early thyroid cancer screening. We propose a deep learning model, the DVT model, which combines transformer DNN and transfer learning techniques to integrate time series data and address small sample sizes and high noise.ResultsThe experimental results show that the DVT model achieves a prediction accuracy of 0.96, AUROC of 0.97, specificity of 1, and sensitivity of 0.94. These results indicate that the DVT model is a highly effective tool for early thyroid cancer screening.ConclusionThe DVT model has the potential to assist clinicians in identifying potential thyroid cancer patients and reducing patient expenses. Our study provides a new approach to thyroid cancer screening using enhanced CT scans and demonstrates the effectiveness of deep learning techniques in addressing the challenges associated with CT-based models.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251323168"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11960174/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143754597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular Mechanisms and Therapeutic Prospects of Immunotherapy and Targeted Therapy in Primary Central Nervous System Lymphoma.","authors":"Lin Zhong, Anqing Lu, Xiyue Lu, Xiaoyin Liu, Lujia Cao, Shihong Zhu, SiJun Diao, Xu Cheng, Hongwei Wu, Jing Chen","doi":"10.1177/15330338251319394","DOIUrl":"10.1177/15330338251319394","url":null,"abstract":"<p><p>Primary central nervous system lymphoma (PCNSL) is a very rare extranodal non-Hodgkin's lymphoma confined to the brain, eyes, spinal cord, and cerebrospinal fluid (CSF). This disease is highly aggressive. For decades, high-dose methotrexate-based induction regimens have been the standard treatment for PCNSL and have significantly improved patient overall survival (OS). However, some patients still experience disease recurrence or develop drug resistance. With a deeper understanding of the pathophysiology of PCNSL, various therapies, including CD20 monoclonal antibodies, Bruton's tyrosine kinase (BTK) inhibitors, immunomodulatory drugs, immune checkpoint inhibitors, phosphoinositide 3-kinase (PI3 K)/mammalian target of rapamycin(mTOR) inhibitors, and chimeric antigen receptor (CAR) -T cells are increasingly being applied and have demonstrated considerable efficacy. These therapies have paved the way for novel treatment strategies in PCNSL, representing a highly promising field. Investigating the mechanisms, specific targets, and signaling pathways, as well as interactions with the tumor microenvironment (TME), can provide a solid foundation for further exploration and potentially enhance the optimization of treatment approaches for PCNSL. This review seeks to explore the characteristics of the TME in PCNSL, elucidate the molecular mechanisms of various immunotherapies and targeted therapies, examine their interactions with the TME, and summarize the advancements in the research of PCNSL immunotherapy and targeted therapy.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251319394"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11800258/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143256471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MR-Guided Adaptive Radiotherapy in Localized Prostate Cancer.","authors":"Andrea Gaetano Allegra, Luca Nicosia, Michele Rigo, Nicola Bianchi, Riccardo Filippo Borgese, Antonio De Simone, Niccolò Giaj-Levra, Davide Gurrera, Stefania Naccarato, Edoardo Pastorello, Francesco Ricchetti, Gianluisa Sicignano, Ruggero Ruggieri, Filippo Alongi","doi":"10.1177/15330338241297231","DOIUrl":"10.1177/15330338241297231","url":null,"abstract":"<p><p>MR-guided radiotherapy (MRgRT) is novel treatment modality in Radiation Oncology that could allow a higher precision and tolerability of Radiation Treatments. This modality is possible due to dedicated systems consisting of a MR scanner mounted on a conventional linac and software that permit daily online treatment plan adaptation. Prostate cancer (PC) is one of the most common malignancies in RO clinical practice and currently under investigation with this new technology. The focus of this review is to describe the current state of the art and clinical results of MRgRT in the treatment of PC. The available technology are briefly described, as well as the published literature and possible future applications.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338241297231"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11770696/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143047974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Analysis of Bladder Volume Consistency Using Portable Ultrasound Scanners and Biofeedback in Radiotherapy for Pelvic Tumors.","authors":"Haitao Wang, Lu Zeng, Quan Zhong, Zhonghua Deng, Renming Zhong","doi":"10.1177/15330338251333645","DOIUrl":"https://doi.org/10.1177/15330338251333645","url":null,"abstract":"<p><p>PurposeTo evaluate the accuracy of two bladder scanners (BS) in measuring bladder volume (BV) during radiotherapy (RT), and explore the influence of two bladder filling methods and patients' subjective urinary sensation on the consistency of BV.MethodsForty-two patients with pelvic tumors were divided into two groups: Group A (20 patients) and Group B (22 patients). Before the planning CT and each treatment session, all patients drank 500 mL of water after emptying their bladder and rectum. Group A waited for patients to provide feedback on urination, while Group B waited for 1 h. Subsequently, three consecutive measurements using two BSs were performed. The average volumes measured by the BS Padscan HD5 and Padscan HDW1 were recorded as BSHD5-v and BSHDW1-v, respectively. The differences between BSHD5-v, BSHDW1-v, and the BV obtained from planning CT (CT-v) or cone beam CT (CBCT) (CBCT-v) were assessed. The consistency between CBCT-v and CT-v in two patient groups was calculated. Urinary sensation score BV (V_SC) was determined by the patient's urge to urinate score and CT-v.ResultsThe average CT-v or CBCT-v was 280 mL (range 78-710 mL, SD = 119 mL). BSHD5-v had an average of 271 mL (range 61-611 mL, SD = 115 mL), with a significant correlation with CT-v or CBCT-v (R = 0.89, p < 0.001). BSHDW1-v averaged 267 mL (range 92-634 mL, SD = 77 mL), positively correlated with CT-v or CBCT-v (R = 0.70, p < 0.001). Group A's CBCT-v proportions within ±20%, ± 30%, and ±50% of CT-v were 51.20%, 66.90%, and 91.90%, respectively, contrasting with Group B's 26.2%, 41.1%, and 67.7%. V_SC exhibited a positive association with CBCT-v (R = 0.59, p < 0.001).ConclusionsConsistent and reproducible bladder volume was obtained by using Padscan HD5 and Padscan HDW1. The Padscan HD5 demonstrated greater consistency and accuracy. Furthermore, the urinary feedback method has a more consistent bladder volume than the fixed-time method.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251333645"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12056319/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143987735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}